The global Pruritus Therapeutics market size is expected to reach USD 11.34 billion by 2030, registering a CAGR of 4.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Growing worldwide prevalence of atopic dermatitis, allergic contact dermatitis, and urticaria is expected to drive market growth during the forecast period. The introduction of new products based on scientific mechanistic understanding such as the identification of new T-cell subsets, particularly Th17, and Th22 and the patent expiration of PROTOPIC (tacrolimus) is expected to open up new avenues for manufacturers to capitalize on over the forecast period.
Corticosteroids were the leading product segment in 2013 owing to high efficacy exhibited by this class of drugs in treating pruritic conditions by reducing inflammation and itching. Topical applications of corticosteroids have been found to be extremely effective in the treatment and maintenance therapies pertaining to pruritus.
Request a free sample copy or view report summary: Pruritus Therapeutics Market Report
Corticosteroids dominated the market and accounted for a share of 28.1% in 2024. Antihistamines are expected to register significant growth over the forecast period.
Hospital pharmacies dominated the market and accounted for a share of 49.8% in 2024. Online pharmacies are projected to grow at the fastest CAGR of 5.9% over the forecast period.
North America pruritus therapeutics market dominated the global market with a revenue share of 38.7% in 2024. The pruritus therapeutics market in the U.S. dominated the North America pruritus therapeutics market with a revenue share of 90.1% in 2024.
Asia Pacific pruritus therapeutics market is expected to register the fastest CAGR of 6.1% in the forecast period.India pruritus therapeutics market is expected to grow at the fastest rate over the forecast period in the Asia Pacific market.
Grand View Research has segmented global pruritus therapeutics market report based on disease, product, distribution channel, and region:
Pruritus Therapeutics Disease Outlook (Revenue, USD Million, 2018 - 2030)
Atopic Dermatitis
Allergic Contact Dermatitis
Urticaria
Others
Pruritus Therapeutics Product Outlook (Revenue, USD Million, 2018 - 2030)
Corticosteroids
Antihistamines
Local Anesthetics
Counterirritants
Immunosuppressant
Calcineurin Inhibitors
Others
Pruritus Therapeutics Distribution Chanel Outlook (Revenue, USD Million, 2018 - 2030)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Pruritus Therapeutics Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of Pruritus Therapeutics Market
AbbVie Inc.
Amgen, Inc.
Astellas Pharma Inc.
Bristol-Myers Squibb
Cara Therapeutics
GSK plc
Novartis AG
Pfizer Inc.
Sanofi
Teva Pharmaceutical Industries Ltd
"The quality of research they have done for us has been excellent..."